{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:46:17Z","timestamp":1792658777369,"version":"4.5.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7,31]]},"DOI":"10.1097\/qad.0b013e3283550e20","type":"journal-article","created":{"date-parts":[[2012,4,27]],"date-time":"2012-04-27T09:46:59Z","timestamp":1335520019000},"page":"1523-1528","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment"],"prefix":"10.1097","volume":"26","author":[{"given":"J. Mirjam","family":"Oudijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mulenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chifumbe","family":"Chintu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepta","family":"Merry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Sarah","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210130","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jac\/dkm484","article-title":"Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.","volume":"61","author":"Cohen","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R2-9-20210130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1086\/505210","article-title":"Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.","volume":"43","author":"Manosuthi","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R3-9-20210130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.qai.0000214808.75594.73","article-title":"Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration.","volume":"42","author":"Ramachandran","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-9-20210130","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/135965350501000809","article-title":"Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.","volume":"10","author":"Autar","year":"2005","journal-title":"Antivir Ther"},{"key":"R5-9-20210130","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00042560-200112150-00007","article-title":"Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.","volume":"28","author":"Ribera","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R6-9-20210130","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","article-title":"Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.","volume":"300","author":"Boulle","year":"2008","journal-title":"JAMA"},{"key":"R7-9-20210130","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/QAD.0b013e3282f4a208","article-title":"Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.","volume":"22","author":"Lhomme","year":"2008","journal-title":"AIDS"},{"key":"R8-9-20210130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/10158782.2009.11441353","article-title":"Childhood tuberculosis guidelines of the Southern African Society for Paediatric Infectious Diseases.","volume":"24","author":"Moore","year":"2009","journal-title":"South Afr J Epidemiol Infect"},{"key":"R10-9-20210130","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/FTD.0b013e3181d75e47","article-title":"Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.","volume":"32","author":"Burger","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R14-9-20210130","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/INF.0b013e3182401c41","article-title":"Pharmacokinetics of nevirapine in human immune deficiency virus and tuberculosis co-infected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.","volume":"31","author":"Prasitsuebsai","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R15-9-20210130","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s13312-011-0153-3","article-title":"Serum nevirapine and efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.","volume":"48","author":"Shah","year":"2011","journal-title":"Indian Pediatr"},{"key":"R17-9-20210130","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/jac\/dkp358","article-title":"Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.","volume":"64","author":"Pollock","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R18-9-20210130","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/01.aids.0000247578.08449.ff","article-title":"An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.","volume":"20","author":"Bartlett","year":"2006","journal-title":"AIDS"},{"key":"R19-9-20210130","doi-asserted-by":"crossref","first-page":"e17273","DOI":"10.1371\/journal.pone.0017273","article-title":"Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.","volume":"6","author":"Frohoff","year":"2011","journal-title":"PLoS One"},{"key":"R20-9-20210130","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1086\/656628","article-title":"Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination baby pills in Zambia: a randomized controlled trial.","volume":"51","author":"Mulenga","year":"2010","journal-title":"Clin Infect Dis"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0b013e3283550e20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T09:55:12Z","timestamp":1687427712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201207310-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,31]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e3283550e20","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7,31]]}}}